Immatics IMTX
NASDAQ IMTX
$9.56 +0.10 (+1.06%)
As of: Sep 4, 2026 · 3:59 PM EDT

Immatics (IMTX) Income from Non-Controlling Interests (2019 - 2024)

Immatics (IMTX) posted Income from Non-Controlling Interests of -$33.6 million for Q2 2021, down 10692.4% sequentially from -$311713.2 in Q2 2020, and down 10692.4% YoY from N/an in Q2 2020.

Analysis

Immatics (IMTX) Income from Non-Controlling Interests (2019 - 2024) Analysis & Trends

Immatics has reported Income from Non-Controlling Interests for 3 years, with the latest figure at -$33.6 million in Q2 2021.

  • Quarterly Income from Non-Controlling Interests fell 10692.4% year-over-year to -$33.6 million in Q2 2021, while the trailing twelve-month figure through Sep 2024 was -$33.6 million (changed N/A YoY) and the FY2020 annual result came in at -$635968.0, up 38.01% from the prior year.
  • Income from Non-Controlling Interests slipped to -$33.6 million in Q2 2021 per IMTX's latest filing, from -$311713.2 in the prior quarter.
  • Over five years, Income from Non-Controlling Interests peaked at -$249049.7 in Q4 2019 and troughed at -$33.6 million in Q2 2021.
  • A 3-year average of -$5.8 million and a median of -$297007.3 in 2019 frame the typical range for Income from Non-Controlling Interests.
  • The sharpest annual moves came in 2020 and 2021: Income from Non-Controlling Interests fell 19.58% in 2020, then slumped 10692.4% in 2021.
  • Over 3 years, Income from Non-Controlling Interests stood at -$249049.7 in 2019, then declined by 25.16% to -$311713.2 in 2020, then plunged by 10692.4% to -$33.6 million in 2021.
  • According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$33.6 million, -$311713.2, and -$302479.3 for Q2 2021, Q2 2020, and Q1 2020 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - 63.60 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Immatics 1.17 Bn 711.21 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 -3.32 Mn
Jun 30, 2021 -33.64 Mn
Dec 31, 2020 1.33 Mn
Jun 30, 2020 -311,713.22
Mar 31, 2020 -302,479.29
Dec 31, 2019 -249,049.73
Sep 30, 2019 -291,535.27
Jun 30, 2019 -260,684.27